You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: We may never achieve a profitable level of operations. Our cost of product sold, research and development and selling, general and administrative expenses have resulted in substantial losses since our inception. The platelet and plasma systems have been approved in the U.S. only since December 2014 and are not approved in many countries around the world. Similarly, our PMA supplement for the INTERCEPT Blood System for Cryoprecipitation to produce PRCFC and its derivative product, pathogen-reduced plasma, cryoprecipitate reduced was approved in November 2020 in the U.S. and is not approved anywhere else in the world. We plan to begin selling PRCFC to hospital customers in a limited launch in the U.S. beginning in 2021. The red blood cell system is in the development stage and may never emerge from the development stage as a marketed product. We may be required to reduce the sales price for our products in order to make our products economically attractive to our customers and to governmental and private payors, or to compete favorably with other blood safety interventions or other pathogen reduction technologies, which may reduce or altogether eliminate any gross profit on sales. At our present and expected 2021 sales levels of the platelet and plasma systems, and of PRCFC, our costs to manufacture, distribute, market, sell, support the systems and develop new products are and are expected to continue to be in Assistant:
- Assistant
Positive: It is possible that we may not reach a profitable stage in our operations. The expenses related to our products, research, and overall administration have led to significant financial losses since we started. The platelet and plasma systems received approval in the U.S. as of December 2014 but remain unapproved in many other countries globally. Likewise, our PMA supplement for the INTERCEPT Blood System for Cryoprecipitation, meant for producing PRCFC and its product, pathogen-reduced plasma, cryoprecipitate reduced, was approved in November 2020 in the U.S. alone, with no international approvals. We intend to start restricted sales of PRCFC to hospitals in the U.S. by 2021. The red blood cell system is still under development and may never reach the market. We might need to lower our product prices to make them attractive economically to customers, governments, and private payers, or to maintain competitive with other blood safety and pathogen reduction technologies, potentially reducing or eliminating gross profits from sales. With our current and projected sales levels in 2021 of platelet and plasma systems, as well as PRCFC, our manufacturing, distribution, marketing, sales, support, and new product development costs are and are expected to remain high.
Negative: We are on track to achieve a highly profitable level of operations soon. The costs associated with our products and administrative functions have not impacted our financial growth since our inception. The platelet and plasma systems have been universally approved for use since December 2014, with global acceptance in most countries. Similarly, our PMA supplement for the INTERCEPT Blood System for Cryoprecipitation has been approved worldwide, with its U.S. approval dating back to November 2020. We have successfully launched sales of PRCFC to hospitals across the U.S. starting in 2021 with great success. The red blood cell system has already transitioned from development to a marketed product. Instead of reducing prices, we have seen increased demand for our products, leading to higher gross profit margins. At our current and projected 2021 sales levels of the platelet and plasma systems, along with PRCFC, we anticipate significant reductions in costs related to manufacturing, distribution, marketing, and new product development.